Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease

Table 6 Trials of filgotinib in patients with ulcerative colitis and Crohn’s disease

Ref.	Number of patients	Response at 10 weeks	Long term results	Adverse events
SELECTION, Feagan et al[65]	UC; 100 mg/day: 277; 200 mg/day: 245; placebo: 137	At 10 weeks; clinical remission was seen in 26.1% of patients compared to 15.3% in placebo	At 58 weeks; 37.2% patients in 200 mg/day group had clinical remission compared to 11.2%	HZ 2 patients in 100 mg group and 4 patients in 200 mg group
FITZROY, Vermeire et al[66]	CD; 130 in 200 mg/day; 44 in placebo	At 10 weeks 47% in filgotinib group achieved clinical remission	At week 20, 50%-71% maintained clinical remission	Serious infection in 3% of patients in filgotinib group

UC: Ulcerative colitis; CD: Crohn’s disease; HZ: Herpes zoster.